RNS Number : 5960Z
Zotefoams PLC
12 January 2024

Zotefoams plc

("Zotefoams" or "Company")

Director / PDMR Shareholding

12 January 2024 - Zotefoams, a world leader in cellular materials technology, announces that it has been informed that a number of transactions in ordinary shares of 5 pence each in the Company ("Ordinary Shares") have been undertaken on behalf of Gary McGrath, Chief Financial Officer, which includes a sale of Ordinary Shares out of a general investment account and subsequent purchase of Ordinary Shares into an ISA account for tax planning purposes. The table below sets out further information on the transactions, which in aggregate amounts to a net sale of 394 Ordinary Shares.

Following these transactions, Gary McGrath's beneficial interest in the Company is 100,492 Ordinary Shares, representing approximately 0.2% per cent. of the Company's issued share capital.

- Ends -

Enquiries:

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO


Gary McGrath, Group CFO




IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen


The information below (set out in accordance with the requirements of EU Market Abuse Regulation) provides further detail:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Gary McGrath

2

Reason for the notification

a)

Position/status

PDMR, Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Zotefoams PLC

b)

LEI

213800B6P256B5XN8D32

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

b)

Nature of the transaction

1) Sale of Ordinary Shares

2) Sale of Ordinary Shares

3) Sale of Ordinary Shares

4) Purchase of Ordinary Shares into Mr McGrath's ISA account

c)

Price(s) and volume(s)

Price(s)

1) £2.6896

2) £3.0066

3) £3.3827

4) £3.4560

Volume(s)

177

191

889

863

d)

Aggregated information

- Aggregated volume

- Aggregated price

n/a - each a single transaction

e)

Date of the transaction

1) 1 July 2022

2) 1 September 2022

3) 25 September 2023

4) 26 September 2023

f)

Place of the transaction

London Stock Exchange, Main Market (XLON)

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAKFAFSELEFA